fromBusiness Matters
1 day agoNYC startup
Novo Nordisk cuts forecasts as Ozempic and Wegovy sales hit by US copycat versions
Novo Nordisk has lowered its revenue and profit forecasts due to sales pressure from unauthorized compounded GLP-1 drugs.
Wegovy is expected to see growth rebound after the FDA ban on compounded versions.